<SEC-DOCUMENT>0001171843-23-007223.txt : 20231121
<SEC-HEADER>0001171843-23-007223.hdr.sgml : 20231121
<ACCEPTANCE-DATETIME>20231121141051
ACCESSION NUMBER:		0001171843-23-007223
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20231117
FILED AS OF DATE:		20231121
DATE AS OF CHANGE:		20231121

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Bisker-Leib Vered
		CENTRAL INDEX KEY:			0001814093

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39696
		FILM NUMBER:		231426638

	MAIL ADDRESS:	
		STREET 1:		C/O COMPASS
		STREET 2:		245 FIRST STREET, 3RD FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Compass Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001738021
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		80 GUEST STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02135
		BUSINESS PHONE:		617-500-8099

	MAIL ADDRESS:	
		STREET 1:		80 GUEST STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02135

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Olivia Ventures, Inc.
		DATE OF NAME CHANGE:	20180419
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2023-11-17</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001738021</issuerCik>
        <issuerName>Compass Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>CMPX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001814093</rptOwnerCik>
            <rptOwnerName>Bisker-Leib Vered</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O COMPASS THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>80 GUEST ST., SUITE 601</rptOwnerStreet2>
            <rptOwnerCity>BOSTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02135</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Operating Officer</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2023-11-17</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>F</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>64415</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>1.50</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1420499</value>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units (&quot;RSUs&quot;)</footnote>
        <footnote id="F2">8,148 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which will vest on November 30 and December 31, 2023. 300,000 of the shares represents unvested restricted stock units (&quot;RSU&quot;) granted to the reporting person on November 16, 2021. 400,000 of the shares represents unvested restricted stock units (&quot;RSU&quot;) granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Vered Bisker-Leib</signatureName>
        <signatureDate>2023-11-21</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
